Purpose

To review safety and efficacy of combined plasma rich in growth factors (PRGF) eye drops and scleral contact lens (SCL) therapy in patients with ocular surface disease.

Methods

Patients with ocular surface disease of various etiologies were screened for at least 3 months of concurrent treatment with PRGF and SCL. Retrospective pre- and post-treatment measurements were collected, including patient satisfaction, severity and frequency of dry eye symptoms measured by a modified Symptom Assessment in Dry Eye (SANDE) questionnaire, visual acuity, and number of concurrent treatments.

Results

26 patients with ocular surface disease were included in the study with 20 patients answering the questionnaire (77% response rate). There were no adverse events reported. Most patients thought the combined therapy was better than previous treatments and would recommend to others (80%, 90% respectively). SANDE scores significantly decreased after use of concurrent therapy. There was a small but significant decrease in the number of other concurrent treatments. Visual acuity was unchanged.

Conclusions

This retrospective cohort study found PRGF used in combination with SCL is safe and significantly decreases symptoms in patients with recalcitrant ocular surface disease.

中文翻译：

---

富含生长因子的血浆与巩膜隐形眼镜联合治疗眼表疾病

目的

评价联合血浆富含生长因子（PRGF）滴眼液和巩膜接触镜（SCL）治疗眼表疾病患者的安全性和有效性。

方法

筛选患有各种病因的眼表疾病的患者，同时接受 PRGF 和 SCL 治疗至少 3 个月。收集了回顾性的治疗前和治疗后测量结果，包括患者满意度、干眼症症状的严重程度和频率，通过改良的干眼症症状评估 (SANDE) 问卷、视力和同时治疗的次数来测量。

结果

26 名眼表疾病患者被纳入研究，其中 20 名患者回答了问卷（77% 的回应率）。没有报告不良事件。大多数患者认为联合治疗优于以前的治疗并会推荐给其他人（分别为 80% 和 90%）。使用同步治疗后，SANDE 评分显着下降。其他并发治疗的数量有小幅但显着的减少。视力没有变化。

结论

这项回顾性队列研究发现，PRGF 与 SCL 联合使用是安全的，并且可以显着减轻顽固性眼表疾病患者的症状。